Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application ...

Cancer treatment decisions are complex, requiring consideration of both medical advancements and individual patient needs, including emotional and physical conditions. There is often a gap between the ...

The UK experienced a notable increase in advanced therapy clinical trials in 2024, reaching 187 ongoing trials. This marks a 7% rise from the previous year. Particularly, phase I trials saw an ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Deborah Finck shared her five-year battle with leiomyosarcoma on social media, amassing over 800,000 followers before her passing. Bob Uecker, a former baseball player and sportscaster, succumbed to ...

Besonders aktuell wurden die digitalen Werbetafeln in der Innenstadt in Betrieb genommen. Diese ermöglichen neben ihrer eigentlichen Aufgabe der Werbeanzeige auch schnelle Informationen zu Wetter, ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Regeneron Pharmaceuticals on Monday presented positive Phase III data for its PD-1 inhibitor Libtayo, which yielded significant survival benefits when used as an adjuvant treatment for patients with ...